MedTrace Logo

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

NCT01106014 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1156

Last updated 2025-10-27

Study results available
· View outcomes & findings →

Summary

The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.

Conditions

Interventions

DRUG

Selexipag

Selexipag 200 µg tablets

DRUG

Placebo

Placebo tablets matching selexipag

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Aline Frey · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-01
Primary Completion
2014-04-01
Completion
2014-10-01

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Canada
  • Chile
  • China
  • Colombia
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Hungary
  • India
  • Ireland
  • Israel
  • Italy
  • Malaysia
  • Mexico
  • Netherlands
  • Peru
  • Poland
  • Romania
  • Russia
  • Serbia
  • Singapore
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01106014 on ClinicalTrials.gov